Placebo-controlled trials of blood pressure-lowering therapies for primary prevention of dementia.

  title={Placebo-controlled trials of blood pressure-lowering therapies for primary prevention of dementia.},
  author={Jan A Staessen and Lutgarde Thijs and Tom Richart and Augustine Nonso Odili and Willem H. Birkenh{\"a}ger},
  volume={57 2},
Placebo-Controlled Trials of Blood Pressure–Lowering Therapies for Primary Prevention of Dementia To the Editor: Hypertension at middle age is a risk factor for vascular and neurodegenerative dementia later in life.1 Because populations are aging, the number of demented patients will grow 2-fold every 20 years, from 24.3 million people in 2000 to 81.1 million by 2040, with 60% living in developing countries.2 The question of whether hypertension is a modifiable risk factor for dementia is… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 32 extracted citations


Publications referenced by this paper.
Showing 1-10 of 15 references

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

  • ADVANCE Collaborative Group
  • Lancet
  • 2007

Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease

  • F Forette, ML Seux, +15 authors R Fagard
  • Arch Intern Med
  • 2003

Similar Papers

Loading similar papers…